Floatz logo

Elranatamab

Bispecific Antibody

Pfizermonoclonal_antibodyPhase 2Active
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
81/ 100

Competitive context

11 Active assets in the Bispecific Antibody cohort.

Asset / SponsorPhaseRating
Benadryl
Pfizer
Phase 2B
Mezigdomide
Pfizer
Phase 2B
DEXAMETHASONE
Pfizer
Phase 2B
Polatuzumab Vedotin
Li Zhiming
Phase 2CCC
Glofitamab
Li Zhiming
Phase 2CCC

View all 11 →

Same molecule, other indications

Elranatamab is also rated in:

plasma cell myelomaDormant
BB
Indicative ·
66 / 100
View asset →
Waldenstrom macroglobulinemiaDormant
BB
Indicative ·
65 / 100
View asset →
HIV infectious diseaseDormant
B
Indicative ·
57 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →